Cardiff Oncology Q3 net loss narrows 21% to $8.86 million
CRDF•Cardiff Oncology’s third-quarter 2026 net loss narrowed 21% year over year to $8.86 million. Royalty revenues rose 43% to $171,000, and cash resources of $33.8 million were expected to fund operations through the third quarter of 2027.
1. Quarterly results
Cardiff Oncology reported a third-quarter 2026 net loss of $8.86 million, down 21% year over year. Royalty revenues rose 43% to $171,000, while operating expenses fell 22% to $9.39 million.
2. Cash and trial plans
Cash resources totaled $33.8 million at September 30, 2026, sufficient to fund operations through the third quarter of 2027. Median progression-free survival remains unreached for the proposed Phase 3 onvansertib regimen, versus approximately 11 months for combined standard-of-care arms. The registrational Phase 3 trial in first-line RAS-mutated metastatic colorectal cancer could start in the first quarter of 2027, subject to financing.
